Breast Cancer
Conditions
Interventions
Observation Group:None
Sponsors
Fudan University Shanghai Cancer Center
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Phase One: 1. Work in a tertiary hospital, including general hospitals and cancer specialist hospitals; 2. Possess at least 10 years of experience in the treatment and research of locally advanced and metastatic HR+ and HER2-BC; 3. The professional rank is chief physician or associate chief physician; 4. Oncologists who have diagnosed and treated at least 10 newly diagnosed patients with locally advanced and metastatic HR+ and HER2-BC in clinical practice over the past 3 months; surgeons who have diagnosed and treated at least 4 newly diagnosed patients with locally advanced and metastatic HR+ and HER2-BC in clinical practice over the past 3 months; radiologists who have diagnosed and treated at least 2 newly diagnosed patients with locally advanced and metastatic HR+ and HER2-BC in clinical practice over the past 3 months; 5. In the past 10 years, served as a member, executive member, vice chairman, chairman, or other similar positions in the breast cancer expert committee, radiotherapy expert committee, or oncology expert committee under the China Anti-Cancer Association (CACA) or the Chinese Society of Clinical Oncology (CSCO). 6. Sign the informed consent form or provide an electronic signature on the consent form for participating in the study. Phase two: For physicians, 1. Working in tertiary A hospital, including general hospital and specialized cancer hospital; 2. Having at least 5-year experience of treating and studying locally advanced and metastatic HR+, HER2- BC; 3. Recruiting physicians in terms of chief physician, vice chief physician or attending physician; 4. Oncologists with at least 10 newly diagnosed locally advanced and metastatic HR+, HER2-BC patients in the past 3 months of clinical practice; surgeons with at least 4 newly diagnosed locally advanced and metastatic HR+, HER2- BC patients in the past 3 months of clinical practice; radiologists with at least 2 newly diagnosed locally advanced and metastatic HR+, HER2- BC patients in the past 3 months of clinical practice; 5. Signing the informed consent or provide an e-signature on the consent form to participate in the study. For patients with locally advanced and metastatic HR+, HER2- BC, the inclusion criteria include: 1. >=18 years old; 2. Female; 3. Having a histologically or cytologically documented HR+, HER2- BC(ER or PR positive criteria: Immunohistochemical (IHC) staining shows nuclear staining in at least 1% of tumor cells at varying intensity. HER2 negative criteria: IHC 0 or 1+; if IHC is 2+, in situ hybridization (ISH) must be performed to confirm negative status.); 4. Having histopathologically confirmed diagnosis of inoperable locally advanced and metastatic HR+, HER2- BC; 5. Within 12 months of start of each line (1st/2nd/3rd/>=4th) of salvage treatment for locally advanced and metastatic HR+, HER2- BC; 6. Patient is able to read and understand the questionnaire in his/her local language; 7. Signing the informed consent or provide an e-signature on the consent form to participate in the study.
Exclusion criteria
Exclusion criteria: 1. The HCPs will be excluded if they are unwilling to provide electronic agreement to participate in the survey. 2. The patients will be excluded if their pathological diagnosis are incomplete or had other malignancies within five years prior to participation in this study(Those patients who have had no evidence of recurrence or progression or has required active treatment for that malignancy within the past 5 years can be included.) 3. or is unwilling to provide written informed consent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The distribution of the treatment pattern of locally advanced and metastatic HR+, HER2- BC both from Chinese physicians and patients;The treatment decision-making factors of locally advanced and metastatic HR+, HER2- BC both from Chinese physicians and patients; | — |
Secondary
| Measure | Time frame |
|---|---|
| The systemic treatment regimens of locally advanced and metastatic HR+, HER2- BC in China from Chinese physicians and patients; The treatment decision-making factors of locally advanced and metastatic HR+, HER2- BC on the systemic treatment regimens from Chinese physicians and patients; | — |
Countries
China
Contacts
Public ContactZhang Jian
Fudan University Shanghai Cancer Center
Outcome results
None listed